EpiAxis Therapeutics is a private company developing a pipeline of epigenetic cancer treatments, leading with LSD1 inhibitors. The lead indication is metastatic breast cancer with later extension to many other tumor types, offering significant commercial potential. EpiAxis is undertaking IND-enabling studies for a first-in-human study to commence late 2022. Importantly, the Company has a highly competent management team in place.
Phone (including country code)
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.